Breaking Finance News

Zealand Pharma A S (NASDAQ:ZLDPF) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded Zealand Pharma A S (NASDAQ:ZLDPF) to Hold in a statement released on 6/8/2017.

Having a price of $17.75, Zealand Pharma A S (NASDAQ:ZLDPF) traded 1.36% higher on the day. With the last close down 4.32% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same period. Zealand Pharma A S has recorded a 50-day average of $18.55 and a two hundred day average of $17.93. Volume of trade was down over the average, with 0 shares of ZLDPF changing hands under the typical 22

See Chart Below

Zealand Pharma A S (NASDAQ:ZLDPF)

Zealand Pharma A S has a 52 week low of $14.95 and a 52 week high of $19.51 Zealand Pharma A S’s market capitalization is currently $0.

Brief Synopsis On Zealand Pharma A S (NASDAQ:ZLDPF)

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes. Its products under development include Glepaglutide, a novel GLP-2 analogue in Phase II clinical trials for the treatment of short bowel syndrome; Dasiglucagon, a ready-to-use hypo-pen in Phase II clinical trials to treat acute, severe hypoglycemia, as well as in Phase IIa clinical trials for pump-based diabetes management; Elsiglutide, a novel GLP-2 analogue in Phase II clinical trials to treat chemotherapy-induced diarrhea; and GLP1-GLU, a preclinical stage product for obesity/type 2 diabetes. The company has license agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Helsinn Healthcare S.A.; and Protagonist Therapeutics, Inc. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *